BioCentury
ARTICLE | Clinical News

Bevirimat dimeglumine: Phase IIa data

October 5, 2009 7:00 AM UTC

The open-label Phase IIa 206 trial in 33 evaluable patients showed that food had minimal effect on MPC-4326 exposure. Patients received 300 or 400 mg once-daily or 100 mg twice-daily oral MPC-4326 for...